Showing 2021-2030 of 8159 results for "".
Let's Talk about YouTube and why your Practice should have one
https://practicaldermatology.com/topics/practice-management/let-s-talk-about-youtube-and-why-your-practice-should-have-one/19116/Any form of healthcare, dental and veterinarian practice should have a YouTube account. It is known that people prefer to watch a video to learn and understand something, rather than read an article or look at a picture. YouTube gives your practice the chance to educate your patients or clients.Laser Tattoo Removal and the Use of Stacked Treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-tattoo-removal-and-the-use-of-stacked-treatments/19309/Tattoo removal procedures have been offered since the late 1990's, but are more effective than ever. This improvement is due to the implementation of stack treatments, during which four sessions can be performed at one time. To show the advances in this procedure, Dr. Joel Schlessinger walks you thrSocial Media: Mass Med Society
https://practicaldermatology.com/topics/practice-management/mass-med-society/19360/Massachusetts Medical Society: Social Media Pitfalls and Opportunities, including inadvertent disclosure and security.Medlite - What Physicians are Saying
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/medlite-what-physicians-are-saying/19453/Impressive statements from Doctors using the Medlite laser are given. The benefits and outcomes of specific cases are discussed.Journal Club: Tapinarof Cream in Pediatric Patients
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-tapinarof-cream-in-pediatric-patients/32399/Practical Dermatology Editorial Board member Peter Lio, MD, speaks with Mona Shahriari, MD, about the Journal of Dermatology article "A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis," and the general importance ofJournal Club: Treating Itch and Lessons from the IL-4 and IL-13 Blockade
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-treating-itch-and-lessons-from-the-il-4-and-il-13-blockade/27025/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Matthew Zirwas, MD, about how evaluations of itch can lead to treatment for atopic dermatitis, and his Journal of Drugs in Dermatology article "Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade."Cosmetic Options in Female Hair Loss
https://practicaldermatology.com/issues/august-2025/female-hair/36697/Female hair loss is a common issue addressed by dermatologists. It is a time-consuming problem to assess and treat. This article provides a methodical approach to female hair loss, including cosmetic options.Updates on Psoriasis Biologics
https://practicaldermatology.com/programs/practical-dermatology/updates-on-psoriasis-biologics/35894/Jashin J. Wu, MD, discusses biologics for psoriasis, including a meta-analyses of best biologics for different types of the condition, at Music City SCALE 2025.Hilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.